在2022年第五版世界卫生组织内分泌肿瘤和中枢神经系统肿瘤分类中，垂体腺瘤被重新分类为神经内分泌肿瘤（NET）。这一改变给大多数良性肿瘤带来了肿瘤学标签。为了指导垂体腺瘤患者的预后、治疗和结果，需要一个全面的临床分类体系。垂体腺瘤和NET在形态和超微结构上有一些相似之处。但与NET不同的是，垂体腺瘤高度普遍，但通常是惰性的，很少转变为恶性。本文论述了一个跨学科国际研讨会的结果，讨论了将垂体腺瘤分类为NET的改变的优点和临床意义。许多非组织学因素提供了机制洞察力，并影响了垂体腺瘤的预后和治疗。我们建议发展一个综合分类体系，将临床、遗传、生物化学、放射学、病理学和分子信息整合在一起，适用于所有垂体前叶肿瘤。© 2023. Springer Nature Limited.

In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours (NETs). This change confers an oncology label to neoplasms that are overwhelmingly benign. A comprehensive clinical classification schema is required to guide prognosis, therapy and outcomes for all patients with pituitary adenomas. Pituitary adenomas and NETs exhibit some morphological and ultrastructural similarities. However, unlike NETs, pituitary adenomas are highly prevalent, yet indolent and rarely become malignant. This Perspective presents the outcomes of an interdisciplinary international workshop that addressed the merit and clinical implications of the classification change of pituitary adenoma to NET. Many non-histological factors provide mechanistic insight and influence the prognosis and treatment of pituitary adenoma. We recommend the development of a comprehensive classification that integrates clinical, genetic, biochemical, radiological, pathological and molecular information for all anterior pituitary neoplasms.© 2023. Springer Nature Limited.